CURIS INC
CRISNasdaq
$4.63
↓ -7.0%Jul 17 close · end-of-day
Price
1Y↓ -87.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$89.7M
Enterprise Value
$74.7M
P/E
—
P/S
12.7
P/B
7.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$7.1M
Net Income (TTM)
-$21.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-100.2%
Net Margin
-299.7%
ROE
-166.6%
ROIC
—
Debt / Equity
—
Net Cash
$15.0M
Return 1Y
-87.4%
Company profile
Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial. CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
- CEO
- James E. Dentzer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- curis.com
Management & directors
- Dentzer James EPresident & CEO
- Duvall DianthaCFO
- Hamdy Ahmed MdCMO
- Zung Jonathan B.CDO
Roles derived from SEC Form 4 filings.
Earnings
CRIS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$1.250.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$5.7M |
| Net income | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Diluted EPS | -$0.61 | $0.50 | -$12.14 | -$8.96 | -$6.88 | -$0.58 |
| Operating cash flow | -$25.7M | -$37.6M | -$54.3M | -$38.4M | -$39.6M | -$27.2M |
| Free cash flow | -$26.4M | -$37.6M | -$54.8M | -$38.4M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -229.8% | -395.0% | -521.7% | -482.2% | -408.3% | -60.5% |
| Net margin | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.9M | $3.3M | $2.4M | $2.7M | $3.2M | $1.1M | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.5M | -$10.6M | -$9.0M | -$10.2M | -$8.3M | -$6.9M | $19.6M | -$11.5M |
| Net income | -$11.8M | -$10.1M | -$9.6M | -$10.6M | -$8.6M | -$7.7M | $19.4M | -$24.2M |
| Diluted EPS | -$2.03 | -$1.70 | -$1.10 | -$1.25 | -$0.68 | -$0.49 | $1.84 | -$1.25 |
| Operating cash flow | -$11.1M | -$5.9M | -$9.3M | -$7.3M | -$8.0M | -$5.6M | -$6.4M | -$9.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -491.4% | -360.5% | -268.9% | -426.8% | -300.1% | -218.0% | 1724.0% | — |
| Net margin | -463.6% | -344.3% | -287.5% | -446.1% | -312.6% | -243.4% | 1700.9% | — |
Company news
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-31 | KAITIN KENNETH I | Buy | 10,000 | $0.55 | $5,487.00 | filing |
| 2026-03-20 | Zung Jonathan B.· CDO | C | 66,667 | — | — | filing |
| 2026-03-20 | Hamdy Ahmed MD· CMO | C | 66,667 | — | — | filing |
| 2026-03-20 | Duvall Diantha· CFO | C | 66,666 | — | — | filing |
| 2026-03-20 | Dentzer James E· President & CEO | C | 133,333 | — | — | filing |
| 2026-03-20 | Rubin Marc | C | 26,667 | — | — | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.